Prestige Consumer Healthcare Inc. Revenue in 2024

Prestige Consumer Healthcare Inc. reported $1.1B in revenue for fiscal year 2024. This represents a growth of 4.6% compared to the 2023 figure of $1.1B.

Converting more than 90% of net income into free cash flow is the defining financial characteristic of Prestige Consumer Healthcare. Net income of $195 million in fiscal year 2024 on $1.13 billion in revenue at a 17.3% net margin understates the cash generation because the asset-light model — no owned manufacturing, minimal capital expenditure requirements — means very little of the earnings is consumed by reinvestment in physical assets. The 58.5% gross margin in FY2024 is not stable by accident. It reflects a portfolio concentrated in OTC categories where the cost to manufacture the product is low relative to what consumers pay for the brand's reassurance value, and where private label competition exists but has not succeeded in displacing the category leader despite lower prices. Monistat's category position, for example, has held across multiple decades of private label challenge. Clear Eyes has maintained shelf position despite store brand alternatives at significantly lower price points. Revenue grew from $1.05 billion in 2022 to $1.08 billion in 2023 to $1.13 billion in 2024 — consistent, unspectacular growth. Market capitalization of $4.2 billion at roughly 3.7 times revenue reflects a premium for the free cash flow quality and the durability of the category leadership positions. Adjusted EBITDA margins above 30% on $1.13 billion in revenue generate enough cash to fund both brand investment and meaningful debt reduction or shareholder returns. The North American OTC Healthcare segment accounts for 85% of total net sales, with Digestive Health, Eye Care, and Fungal Care as the largest therapeutic categories. That concentration means the financial results are driven by a relatively small number of brands in a relatively small number of categories — which is both the source of the margin quality and the source of the concentration risk if any of those category positions deteriorated significantly.